Validation of a monoclonal unconjugated estriol antibody for use in prenatal maternal serum screening
Journal of Medical Screening · 2023
DOI: 10.1177/09691413231160109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Screening, 2023. Verfasst von Geralyn M Lambert-Messerlian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Women and Infants Hospital and the Alpert Medical School at Brown University, Providence, RI, USA. Hauptthemen laut MEDLINE: Down Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Beckman Coulter, Inc..
Abstract (Originalsprache)
Objectives
Unconjugated estriol (uE3) is used as a marker for fetal aneuploidy in maternal serum screening tests. The goal of this study was to examine the validity of a new immunoassay for uE3 that uses a monoclonal antibody (m-uE3) rather than the more commonly used polyclonal antibody (p-uE3).
Setting
Assays were performed in the Special Chemistry laboratory at Women and Infants Hospital of Rhode Island.
Methods
Residual fresh ( n = 100) and frozen ( n = 533) second trimester serum samples from routine clinical care were tested using p-uE3 and/or m-uE3 assays. Assay results were compared between methods using Bland–Altman plots. A median equation was developed for m-uE3 results. Down syndrome risks were compared between the two assays in a case–control sample set (21 cases each matched with five controls for the completed week of gestation, duration of freezer storage and race).
Results
Log-transformed serum uE3 levels were highly correlated between the assays ( r = 0.93, p < 0.001), with the m-uE3 assay levels yielding, on average, 23% higher (standard deviation of differences in log uE3 concentrations = 0.07) results. Assay and gestation-based median equations were calculated and used to convert m-uE3 concentrations to multiples of the median (MoM). The m-uE3 MoM values fit a log Gaussian distribution well with a log standard deviation of 0.11. Down syndrome risk results were not significantly different between assays.
Conclusions
The m-uE3 assay, with results expressed in MoMs, is suitable for screening and as a monoclonal-based assay offers the advantage of a predictable and indefinite supply of antibody to perform the assay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Women and Infants Hospital and the Alpert Medical School at Brown University, Providence, RI, USA.
- Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
- Institute of Health Informatics, University College London, London, UK.
ORCID-Profile: Geralyn M Lambert-Messerlian, Jonathan P Bestwick, Nicholas J Wald
Förderung
- Beckman Coulter, Inc.
Zitieren
APA
Lambert-Messerlian, G. M., Bestwick, J. P., & Wald, N. J. (2023). Validation of a monoclonal unconjugated estriol antibody for use in prenatal maternal serum screening. Journal of Medical Screening. https://doi.org/10.1177/09691413231160109
Vancouver
Lambert-Messerlian GM, Bestwick JP, Wald NJ. Validation of a monoclonal unconjugated estriol antibody for use in prenatal maternal serum screening. Journal of Medical Screening. 2023. doi:10.1177/09691413231160109
BibTeX
@article{LambertMesserlian2023,
author = {Lambert-Messerlian, Geralyn M and Bestwick, Jonathan P and Wald, Nicholas J},
title = {Validation of a monoclonal unconjugated estriol antibody for use in prenatal maternal serum screening},
journal = {Journal of Medical Screening},
year = {2023},
doi = {10.1177/09691413231160109}
}
EUVIMED